NO2968302T3 - - Google Patents

Info

Publication number
NO2968302T3
NO2968302T3 NO14725812A NO14725812A NO2968302T3 NO 2968302 T3 NO2968302 T3 NO 2968302T3 NO 14725812 A NO14725812 A NO 14725812A NO 14725812 A NO14725812 A NO 14725812A NO 2968302 T3 NO2968302 T3 NO 2968302T3
Authority
NO
Norway
Application number
NO14725812A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2968302T3 publication Critical patent/NO2968302T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO14725812A 2012-10-26 2014-03-14 NO2968302T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261718966P 2012-10-26 2012-10-26

Publications (1)

Publication Number Publication Date
NO2968302T3 true NO2968302T3 (cg-RX-API-DMAC10.html) 2018-02-03

Family

ID=50545344

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14725812A NO2968302T3 (cg-RX-API-DMAC10.html) 2012-10-26 2014-03-14

Country Status (22)

Country Link
US (2) US9777038B2 (cg-RX-API-DMAC10.html)
EP (1) EP2912013B1 (cg-RX-API-DMAC10.html)
JP (1) JP6272888B2 (cg-RX-API-DMAC10.html)
KR (1) KR102068381B1 (cg-RX-API-DMAC10.html)
CN (2) CN105102425B (cg-RX-API-DMAC10.html)
AU (1) AU2013334122B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015009395A2 (cg-RX-API-DMAC10.html)
CA (1) CA2889592A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119731T1 (cg-RX-API-DMAC10.html)
DK (1) DK2912013T3 (cg-RX-API-DMAC10.html)
ES (1) ES2655034T3 (cg-RX-API-DMAC10.html)
HK (1) HK1253301A1 (cg-RX-API-DMAC10.html)
HU (1) HUE036887T2 (cg-RX-API-DMAC10.html)
IL (1) IL238454B (cg-RX-API-DMAC10.html)
MX (1) MX361653B (cg-RX-API-DMAC10.html)
NO (1) NO2968302T3 (cg-RX-API-DMAC10.html)
NZ (2) NZ707389A (cg-RX-API-DMAC10.html)
PL (1) PL2912013T3 (cg-RX-API-DMAC10.html)
PT (1) PT2912013T (cg-RX-API-DMAC10.html)
SG (1) SG11201503247UA (cg-RX-API-DMAC10.html)
SM (1) SMT201700602T1 (cg-RX-API-DMAC10.html)
WO (1) WO2014066819A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
SI3626725T1 (sl) 2014-05-29 2023-04-28 Bar Pharmaceuticals S.R.L. Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
KR102526632B1 (ko) 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
EA033427B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
ES2748692T3 (es) 2014-11-19 2020-03-17 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides
JP6698085B2 (ja) 2014-11-19 2020-05-27 エヌゼットピー ユーケー リミテッド ステロイドFXRモジュレーター製造のための中間体としての6α−アルキル−6,7−ジオン−ステロイド
CN104672290B (zh) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 一种用于预防或治疗fxr‑介导的疾病的药物及其制备方法和用途
ES2905872T3 (es) 2015-02-06 2022-04-12 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia combinada
KR20180052756A (ko) 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체
CN108348533A (zh) * 2015-11-06 2018-07-31 英特塞普特医药品公司 制备奥贝胆酸及其衍生物的方法
US20200262865A1 (en) * 2016-02-15 2020-08-20 Alexander Khoruts Compositions and methods for treating clostridium associated diseases
CA3020698A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating or preventing hepatocellular carcinoma
TW201738254A (zh) * 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
CN109963567A (zh) * 2016-09-30 2019-07-02 英特塞普特医药品公司 胆汁酸衍生物的结晶形式
CA3070837A1 (en) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
US11059854B2 (en) * 2017-07-26 2021-07-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing steroid derivative FXR agonist
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116249536B (zh) 2020-09-18 2026-05-19 沙裴隆有限公司 牛磺脱氧胆酸钠的批量生产方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216015A (en) * 1991-02-05 1993-06-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having hypocholesterolemic properties
DK1392714T3 (da) * 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
DK2040713T3 (da) * 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
WO2010036427A1 (en) 2008-06-17 2010-04-01 Brigham Young University Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods
US8796249B2 (en) * 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
AU2009316484B2 (en) * 2008-11-19 2015-04-16 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives

Also Published As

Publication number Publication date
US10202414B2 (en) 2019-02-12
NZ707389A (en) 2018-08-31
PL2912013T3 (pl) 2018-05-30
EP2912013B1 (en) 2017-10-11
IL238454A0 (en) 2015-06-30
DK2912013T3 (en) 2018-01-15
SMT201700602T1 (it) 2018-03-08
KR20150074062A (ko) 2015-07-01
JP6272888B2 (ja) 2018-01-31
CY1119731T1 (el) 2018-06-27
CN108250264A (zh) 2018-07-06
PT2912013T (pt) 2018-01-03
MX2015005286A (es) 2015-10-29
US20180079776A1 (en) 2018-03-22
KR102068381B1 (ko) 2020-01-20
US20150291653A1 (en) 2015-10-15
EP2912013A4 (en) 2016-06-01
SG11201503247UA (en) 2015-06-29
EP2912013A1 (en) 2015-09-02
US9777038B2 (en) 2017-10-03
AU2013334122A1 (en) 2015-05-14
CN105102425B (zh) 2018-04-10
WO2014066819A1 (en) 2014-05-01
HK1214239A1 (zh) 2016-07-22
HUE036887T2 (hu) 2018-08-28
ES2655034T3 (es) 2018-02-16
CN105102425A (zh) 2015-11-25
NZ745013A (en) 2019-08-30
MX361653B (es) 2018-12-13
HK1253301A1 (zh) 2019-06-14
JP2015533852A (ja) 2015-11-26
IL238454B (en) 2018-11-29
BR112015009395A2 (pt) 2017-07-04
CA2889592A1 (en) 2014-05-01
AU2013334122B2 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
BR112014017635A2 (cg-RX-API-DMAC10.html)
BR112014017614A2 (cg-RX-API-DMAC10.html)
BR112014017625A2 (cg-RX-API-DMAC10.html)
BR112014017659A2 (cg-RX-API-DMAC10.html)
BR112014017592A2 (cg-RX-API-DMAC10.html)
BR112014017638A2 (cg-RX-API-DMAC10.html)
AR092201A1 (cg-RX-API-DMAC10.html)
BR112014025793A2 (cg-RX-API-DMAC10.html)
BR112014024753A2 (cg-RX-API-DMAC10.html)
BR112014017609A2 (cg-RX-API-DMAC10.html)
BR112014017644A2 (cg-RX-API-DMAC10.html)
BR112014017588A2 (cg-RX-API-DMAC10.html)
BR112014013184A8 (cg-RX-API-DMAC10.html)
BR112014017627A2 (cg-RX-API-DMAC10.html)
BR112014017623A2 (cg-RX-API-DMAC10.html)
BR112014017630A2 (cg-RX-API-DMAC10.html)
BR112014017641A2 (cg-RX-API-DMAC10.html)
BR112014017621A2 (cg-RX-API-DMAC10.html)
BR112014017631A2 (cg-RX-API-DMAC10.html)
BR112014017622A2 (cg-RX-API-DMAC10.html)
BR112014017589A2 (cg-RX-API-DMAC10.html)
BR112014017600A2 (cg-RX-API-DMAC10.html)
BR112014017636A2 (cg-RX-API-DMAC10.html)
BR112014017667A2 (cg-RX-API-DMAC10.html)
BR112014017591A2 (cg-RX-API-DMAC10.html)